Clinical trial
Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper…
NCT00220168 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00220168 |
|---|---|
| Title | Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours |
| Official title | A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Upper Gastrointestinal Tumours |
| Intervention type | Drug |
| Interventions | Irinotecan, Capecitabine |
| Enrollment | 33 |
| Start date | Jan 1, 2003 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 16, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: